Sreemanee Raaj Dorajoo
National University of Singapore
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sreemanee Raaj Dorajoo.
Pharmacotherapy | 2017
Sreemanee Raaj Dorajoo; Vincent See; Chen Teng Chan; Joyce Zhen Yin Tan; Doreen Su-Yin Tan; Siti Maryam Binte Abdul Razak; Ting Ting Ong; Narendran Koomanan; Chun Wei Yap; Alexandre Chan
Stratifying patients according to 15‐day readmission risk would be useful in identifying those who may benefit from targeted interventions during and/or following hospital discharge that are designed to reduce the likelihood of readmission.
Journal of Global Oncology | 2017
Alexandre Chan; Zheung Kang Lum; Terence Ng; Tewodros Eyob; Xiao Jun Wang; Jung-woo Chae; Sreemanee Raaj Dorajoo; Maung Shwe; Yan Xiang Gan; Rose Fok; Kiley Wei-Jen Loh; Yee Pin Tan; Gilbert Fan
Purpose With the long-term goal to optimize post-treatment cancer care in Asia, we conducted a qualitative study to gather in-depth descriptions from multiethnic Asian breast cancer survivors on their perceptions and experiences of cancer survivorship and their perceived barriers to post-treatment follow-up. Methods Twenty-four breast cancer survivors in Singapore participated in six structured focus group discussions. The focus group discussions were voice recorded, transcribed verbatim, and analyzed by thematic analysis. Results Breast cancer survivors were unfamiliar with and disliked the term “survivorship,” because it implies that survivors had undergone hardship during their treatment. Cognitive impairment and peripheral neuropathy were physical symptoms that bothered survivors the most, and many indicated that they experienced emotional distress during survivorship, for which they turned to religion and peers as coping strategies. Survivors indicated lack of consultation time and fear of unplanned hospitalization as main barriers to optimal survivorship care. Furthermore, survivors indicated that they preferred receipt of survivorship care at the specialty cancer center. Conclusion Budding survivorship programs in Asia must take survivor perspectives into consideration to ensure that survivorship care is fully optimized within the community.
Diabetes Research and Clinical Practice | 2017
Sreemanee Raaj Dorajoo; Joceline Shi Ling Ng; Jessica Hui Fen Goh; Su Chi Lim; Chun Wei Yap; Alexandre Chan; Joyce Yu-Chia Lee
AIMS To evaluate the association between HbA1c coefficient of variation (HbA1c-CV) and 3-year new-onset albuminuria risk. METHODS A retrospective cohort study involving 716 normoalbuminuric type 2 diabetes patients was conducted between 2010 and 2014. HbA1c-CV was used to categorize patients into low, moderate or high variability groups. Multivariate logistic models were constructed and validated. Integrated discrimination (IDI) and net reclassification (NRI) improvement indices were used to quantify the added predictive value of HbA1c-CV. RESULTS The mean age of our cohort was 56.1±12.9years with a baseline HbA1c of 8.3±1.3%. Over 3-years of follow-up, 35.2% (n=252) developed albuminuria. An incremental risk of albuminuria was observed with moderate (6.68-13.43%) and high (above 13.44%) HbA1c-CV categories demonstrating adjusted odds ratios of 1.63 (1.12-2.38) and 3.80 (2.10-6.97) for 3-year new-onset albuminuria, respectively. Including HbA1c-CV for 3-year new-onset albuminuria prediction improved model discrimination (IDI: 0.023, NRI: 0.293, p<0.05). The final model had a C-statistic of 0.760±0.018 on validation. CONCLUSION HbA1c-CV improves 3-year prediction of new-onset albuminuria. Together with mean HbA1c, baseline urine albumin-to-creatinine ratio and presence of hypertension, accurate 3-year new-onset albuminuria prediction may be possible.
Diseases of The Colon & Rectum | 2017
Winson Jianhong Tan; Sreemanee Raaj Dorajoo; Madeline Yen Min Chee; Wah Siew Tan; Fung Joon Foo; Choong Leong Tang; Min Hoe Chew
BACKGROUND: A prognostic scoring model has been devised previously to predict survival following primary tumor resection in patients with metastatic colorectal cancer and unresectable metastases. This has yet to be validated. OBJECTIVE: The main objectives of this study are to validate the proposed prognostic scoring model and create an interactive online calculator to estimate an individual’s survival after primary tumor resection. DESIGN: Clinical data and survival outcomes of patients were extracted from a prospectively maintained database. Patients were categorized into good, moderate, or poor survivor groups based on the previously proposed scoring algorithm. Discrimination was assessed and recalibration was performed, with the recalibrated model implemented as an interactive Web application to provide individualized survival probability. SETTINGS: This study was conducted at a tertiary referral center. PATIENTS: The study included 324 consecutive patients with metastatic colorectal carcinoma and unresectable metastases who underwent primary tumor resection between January 2008 and December 2013. MAIN OUTCOME MEASURES: The primary outcome measured was overall survival. RESULTS: Three hundred twenty-four patients were included in the study. Median survival in the good, moderate, and poor prognostic groups was 56.8, 25.7, and 19.9 months (log rank test, p = 0.003). The &kgr; statistic was 0.638 and R2D was 0.101. Significant differences in survival were found between the moderate and good prognostic groups (HR, 2.79; 95% CI, 1.51–5.15; p = 0.001) and between poor and good prognostic groups (HR, 4.12; 95% CI, 1.98–8.55; p < 0.001). The model was implemented as an interactive online calculator to provide individualized survival estimation after primary tumor resection (http://bit.ly/Stage4PrognosticScore). LIMITATIONS: Selection bias and single-center data preclude the generalizability of the proposed model. Information regarding the severity or likelihood of developing symptoms from the primary tumor were also not accounted for in the prognostic scoring model proposed. CONCLUSIONS: The prognostic scoring model provides good prognostic stratification of survival after primary tumor resection and may be a useful tool to predict survival after primary tumor resection. See Video Abstract at http://links.lww.com/DCR/A330.
Psycho-oncology | 2018
Terence Ng; Sreemanee Raaj Dorajoo; Yick Ching Lam; Hui Ling Yeo; Maung Shwe; Yan Xiang Gan; Koon Mian Foo; Wei-Jen Kiley Loh; Si-Lin Koo; Amit Jain; Guek Eng Lee; Rebecca Dent; Yoon Sim Yap; Raymond Ng; Alexandre Chan
Currently, there are no studies that have established the self‐perceived cognitive trajectories experienced by breast cancer patients (BCPs) post‐chemotherapy. Therefore, we characterized the long‐term trajectory of self‐perceived cognitive function among Asian early‐stage BCPs using the minimal clinically important difference of a subjective measure of cognitive function.
International Journal of Colorectal Disease | 2016
Sreemanee Raaj Dorajoo; Winson Jianhong Tan; S. X. Koo; Wah-Siew Tan; Min-Hoe Chew; Choong-Leong Tang; H. L. Wee; C. W. Yap
Breast Cancer Research and Treatment | 2018
Jung-woo Chae; Peh Siang Chua; Terence Ng; Angie Hui Ling Yeo; Maung Shwe; Yan Xiang Gan; Sreemanee Raaj Dorajoo; Koon Mian Foo; Kiley Wei-Jen Loh; Si-Lin Koo; Wen Yee Chay; Tira Jing Ying Tan; Sok Yuen Beh; Elaine Hsuen Lim; Guek Eng Lee; Rebecca Dent; Yoon Sim Yap; Raymond Ng; Han Kiat Ho; Alexandre Chan
Supportive Care in Cancer | 2017
Xiao Jun Wang; Denise Yun Ting Goh; Sreemanee Raaj Dorajoo; Alexandre Chan
Journal of Gastrointestinal Cancer | 2017
Winson Jianhong Tan; H. Tan; Sreemanee Raaj Dorajoo; Fung Joon Foo; Choong Leong Tang; Min Hoe Chew
Journal of Clinical Oncology | 2017
Jung-woo Chae; Peh Siang Chua; Terence Ng; Hui Ling Angie Yeo; Maung Shwe; Yan Xiang Gan; Sreemanee Raaj Dorajoo; Koon Mian Foo; Kiley Wei-Jen Loh; Si-Lin Koo; Wen Yee Chay; Tira Jing Ying Tan; Sok Yuen Beh; Hsuen Elaine Lim; Guek Eng Lee; Rebecca Dent; Yoon Sim Yap; Raymond Ng; Han Kiat Ho; Alexandre Chan